Market Research Logo

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
  • The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Overview
Therapeutics Development
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Stage of Development
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Therapy Area
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Indication
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Companies
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Universities/Institutes
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Companies Involved in Therapeutics Development
Abeome Corporation
Alnylam Pharmaceuticals, Inc.
AlphaMab Co., Ltd
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Avacta Group Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
CBT Pharmaceuticals Inc
CytomX Therapeutics, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genosco
ImmunoCellular Therapeutics, Ltd.
Immunocore Limited
IO Biotech ApS
Kadmon Corporation, LLC
Kymab Limited
MedImmune, LLC
Merck KGaA
Merus NV
Novartis AG
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals Inc
Shanghai Henlius Biotech Co., Ltd.
Sorrento Therapeutics, Inc.
Sutro Biopharma, Inc.
Theravectys SA
Tikcro Technologies, Ltd.
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drug Profiles
ALN-PDL - Drug Profile
Antibody to Inhibit PD-L1 for Oncology - Drug Profile
Antisense Oligonucleotide to Inhibit PD-L1 for Oncology - Drug Profile
atezolizumab - Drug Profile
avelumab - Drug Profile
AZD-1775 + durvalumab - Drug Profile
Biologic to Inhibit PD-L1 for Immunology - Drug Profile
BMS-936559 - Drug Profile
CA-170 - Drug Profile
CA-327 - Drug Profile
CBA-0710 - Drug Profile
CBT-502 - Drug Profile
Cellular Immunotherapy to Inhibit PD-L1 for Oncology - Drug Profile
CX-072 - Drug Profile
dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile
durvalumab - Drug Profile
durvalumab + gefitinib - Drug Profile
durvalumab + IMCgp-100 + tremelimumab - Drug Profile
durvalumab + MEDI-0562 - Drug Profile
durvalumab + MEDI-0680 - Drug Profile
durvalumab + monalizumab - Drug Profile
durvalumab + oleclumab - Drug Profile
durvalumab + selumetinib sulfate - Drug Profile
durvalumab + tremelimumab - Drug Profile
FAZ-053 - Drug Profile
GNS-1480 - Drug Profile
HLX-10 - Drug Profile
HLX-20 - Drug Profile
HTI-1316 - Drug Profile
IO-103 - Drug Profile
KD-033 - Drug Profile
KN-035 - Drug Profile
KY-1003 - Drug Profile
LY-3300054 - Drug Profile
MCLA-145 - Drug Profile
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile
Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile
Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile
Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile
Monoclonal Antibody to Inhibit PDL1 for Oncology - Drug Profile
Monoclonal Antibody to Target EGFR and to Inhibit PD-L1 for Oncology - Drug Profile
Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile
Recombinant Proteins to Inhibit PD-L1 for Solid Tumor - Drug Profile
Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile
SNPDL-01 - Drug Profile
STIA-1011 - Drug Profile
STIA-1012 - Drug Profile
STIA-1014 - Drug Profile
STIA-1015 - Drug Profile
Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile
WBP-3155 - Drug Profile
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Dormant Projects
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Discontinued Products
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Abeome Corporation, H2 2016
Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
Pipeline by AlphaMab Co., Ltd, H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by Aurigene Discovery Technologies Limited, H2 2016
Pipeline by Avacta Group Plc, H2 2016
Pipeline by BeiGene, Ltd., H2 2016
Pipeline by Bristol-Myers Squibb Company, H2 2016
Pipeline by CBT Pharmaceuticals Inc, H2 2016
Pipeline by CytomX Therapeutics, Inc., H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by Genosco, H2 2016
Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016
Pipeline by Immunocore Limited, H2 2016
Pipeline by IO Biotech ApS, H2 2016
Pipeline by Kadmon Corporation, LLC, H2 2016
Pipeline by Kymab Limited, H2 2016
Pipeline by MedImmune, LLC, H2 2016
Pipeline by Merck KGaA, H2 2016
Pipeline by Merus NV, H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by PsiOxus Therapeutics Limited, H2 2016
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
Pipeline by Sorrento Therapeutics, Inc., H2 2016
Pipeline by Sutro Biopharma, Inc., H2 2016
Pipeline by Theravectys SA, H2 2016
Pipeline by Tikcro Technologies, Ltd., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report